Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-08-07
Recursion Pharmaceuticals, Inc.
Recursion develops drug candidates and discovery collaborations using an AI-native, automated lab platform that combines proprietary biological data, chemistry, and clinical workflows.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Industrialized Discovery Still Needs Human Proof
A real data-and-lab moat gives this platform more substance than a thin AI wrapper. The rerating case is credible, but it still depends on clinical translation becoming repeatable rather than merely impressive.

Analysis

Thesis
Recursion is a cash-backed option on turning proprietary wet-lab data, automated experiments, and AI agents into repeatable clinical proof; if REC-4881 gets a cleaner path and at least one more internal program validates in humans, value capture can shift from lumpy collaboration revenue toward owned-product, milestone, and royalty economics by 2031.
Last Economy Alignment
Recursion benefits from cheaper cognition because its owned wet-lab data, automated labs, and program engine become more valuable as AI improves. The score stops short of very high because value capture is not seat-based and agent bypass risk is low, but regulators and human clinical outcomes still decide whether the platform becomes durable drug revenue.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.2x (from 5 most recent analyses)
Reasoning
The upside is mainly a proof-and-rerating story, not a heroic blockbuster forecast. If one internal asset reaches a credible commercialization path, partner milestones keep compounding, and Recursion standardizes more of its external discovery work into repeatable higher-value offerings, investors can value it less like outsourced discovery and more like a product engine with multiple shots on goal.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not whether Recursion can run AI-driven discovery; it is whether the engine repeatedly produces human clinical proof before cash burn or partner concentration weakens bargaining power. REC-4881 FDA-path clarity is the dominant gate, a second internal proof point is next, and both matter more than incremental model improvements.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.58
They own the experimental data and lab loop that gets smarter every time it runs, so better AI should make their engine more valuable. The risk is simple: if that engine does not keep producing real drugs and partner wins, customers will treat it like an expensive discovery service.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.25
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case